Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price […]
